Genfit is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology.
Quote | Genfit Ord (OTCMKTS:GNFTF)
Last: | $5.53 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $5.53 |
High: | $0 |
Low: | $0 |
Volume: | 150 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Genfit Ord (OTCMKTS:GNFTF)
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...
Message Board Posts | Genfit Ord (OTCMKTS:GNFTF)
Subject | By | Source | When |
---|---|---|---|
GNFT - Friday Rundown, Monday Expectations | Jake L | investorshub | 12/18/2021 5:40:03 AM |
GNFT formally axes NASH drugwill continue work on | DewDiligence | investorshub | 07/22/2020 8:52:53 PM |
Genfit claims advance in non-invasive NASH diagnostic: #msg-132439027. | DewDiligence | investorshub | 06/23/2017 3:23:36 PM |
Phase-3 NASH trial has slower-than-expected enrollment: #msg-130748127. | DewDiligence | investorshub | 04/24/2017 3:32:42 PM |
Big event happening March 9th!!! | Orangefan1974 | investorshub | 03/03/2017 12:25:00 AM |
News, Short Squeeze, Breakout and More Instantly...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence ...